Adaptimmune Therapeutics PLC — Director's Dealing 2020

Jan 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-01-16

Reporting Person: Norry Elliot (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-16	Option to purchase Ordinary Shares	$0.74	A	201600	Acquired	2030-01-16	Ordinary Shares (201600)	Direct
2020-01-16	Option to purchase Ordinary Shares	$0.0013	A	135600	Acquired		Ordinary Shares (135600)	Direct

Footnotes

F1: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 50,400 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 4,200 Ordinary Shares on the sixteenth of each month from February 16, 2021 through January 16, 2024.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1. 302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 33,900 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 33,900 Ordinary Shares on the sixteenth of each January from January 16, 2022 through January 16, 2024.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.